Teva Pharm profit misses estimates as generic drugs revenue slips

Israeli drugmaker Teva Pharmaceutical Industries reported on Wednesday a lower-than-expected rise in second-quarter profit, weighed down by a decline in revenue from generic medicines.

• It said it earned 2 cents per diluted share, excluding one-time items, in April to June quarter, down from 66 cents a share a year earlier.
• Revenue edged down 1% in dollar terms to $4.1 billion, with Teva citing lower generic drug sales.
• Analysts had forecast earnings of 27 cents per share ex-items on revenue of $4.02 billion, LSEG I/B/E/S data showed.
• Teva's results included expenses related to its June purchase of Emalex Biosciences for more than $700 million.
• It slightly raised its 2026 revenue estimate to $16.5-$16.85 billion, versus $17.3 billion in 2025. Due to the Emalex purchase that reduces EPS by about 66 cents, Teva now projects adjusted EPS in 2026 of $1.91-$2.11, compared with $2.93 in 2025.